×
Abstract CT123: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in advanced wild type BRAF melanoma
Middleton MR., Schadendorf D., Danson S., Marshall E., Corrie P., Love SB., Mohammed SB., Scudder C., Goff M.
DOI
10.1158/1538-7445.am2017-ct123
Type
Conference paper
Publisher
American Association for Cancer Research
Publication Date
01/07/2017